- Screening
- Baseline
- In the process of the treatment
- At the end of the treatment
- Follow-up 1
- Follow-up 2
- Follow-up 3
- Management system of participants
- Speciman management system
- Data management system
- ADR/ADE management system
- Madicine management system
- Instruments management system
- SOPs
- Research team
- Design, Methods
- Management of the progress
- General information
- Physical examination
- Blood Routine Tests
- Urine and Stool Routine Tests
- Blood Electrolytes Tests
- Coagulation Function Tests
- Serum Liver Function Tests
- HBV Markers Test
- Renel Function Test
- Heat Function Examination
- Blood Cell Morphology
- Image Examinations
- Nervous System Examination
- Lung Function Examination
- Blood Gas Analysis
- Physical Ability Examination
- Health Relative Quality of Life
diastolic pressure (start) | 81 |
systolic pressure (start) | 121 |
BMI (start) | 23.6 |
Weight (start) | 51.6 |
BMI (week 4) | 23.2 |
Weight (week 2) | 50.8 |
Height (start) | 148 |
BMI (week 2) | 23.3 |
Weight (week 2) | 51.0 |
IFABP (start) | 4.2 |
TNF-a (start) | 0.9 |
IL-6 (start) | 0.4 |
HbA1C (start) | 7.1 |
GLU-2hr (start) | 210 |
GLU-AC (start) | 143 |
TG (start) | 73 |
- Management for Progress
- Physical examination
- Blood Routine Tests
- Urine and Stool Routine Tests
- Serum Electrolytes Tests
- Liver Function Tests
- HBV Markers Test
- Renel Function Test
- Heat Function Examination
- Image Examinations
- Blood Cell Morphology
- Nervous System Examination
- Lung Function Examination
- Blood Gas Analysis
- Physical Sbility Examination
- Health Relative Quality of Life
diastolic pressure (week 6) | 75.0 |
systolic pressure (week 6) | 120.0 |
BMI (week 6) | 23.3 |
Weight (week 6) | 51.0 |
TG (end) | 96.0 |
IFABP (end) | 5.4 |
TNF-a (end) | 1.1 |
IL-6 (end) | 0.6 |
HbA1C (end) | 6.9 |
GLU-2hr (end) |
|
GLU-AC (end) | 122.0 |